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Open aSummary
Background: To correctly estimate the cost-effectiveness of treatments that reduce COPD
exacerbations, the utility gains from preventing exacerbations need to be measured. This
requires utility measurement during exacerbations.
Aim: To assess the ability of the EQ-5D to detect the recovery from moderate COPD exacerba-
tions.
Methods: In the US, 65 COPD and/or chronic bronchitis patients (40 years old smokers or ex-
smokers with a history of 10 pack-years) were enrolled within 48 h of symptom onset of the
exacerbation. Patients completed the EQ-5D at enrollment and after 7, 14 and 42 days.
Symptoms and medication use were recorded in diaries. Change over time and loss of
quality-adjusted life years (QALYs) due to the exacerbation was estimated. Using standardized
response mean (SRM) as the metric of responsiveness, we compared the responsiveness of the
EQ-5D to the responsiveness of morning peak expiratory flow rate, rescue medication use and
symptom scores. SRMs were also used to assess whether patients with greater improvements in
peak expiratory flow rate, rescue medication use, symptom scores, clinician global impression
of change, and patient global impression of change had a greater improvement in EQ-5D than
patients with smaller improvement.
Results: Mean utility index scores (standard deviation) using the US value set were 0.683
(0.209), 0.726 (0.216), 0.768 (0.169) and 0.760 (0.181) at days 1, 7, 14 and 42, respectively.al Impression of Change; COPD, Chronic Obstructive Pulmonary Disease; EQ-5D, European Quality of
nt’s Global Impression of Change; SD, Standard Deviation; SRM, Standardized Response Mean; QALY,
Year; VAS, (health-related) Visual Analog Scale.
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1196 L.M.A. Goossens et al.The mean of each patient’s lowest index score, either at visit 1 or visit 2, was 0.651 (0.213).
Over the course of 6 weeks there was a highly significant improvement in mean utility. The
greatest improvement was seen between day 7 and day 14. Patients lost on average 0.00896
QALY (0.0086) or 3.27 (3.13) quality-adjusted life days during the exacerbation. The EQ-5D
(SRM: 0.653) was more responsive to change than peak expiratory flow (0.269), rescue medi-
cation use (0.343) and sputum symptom scores (0.322) and equally responsive as cough
(0.587) and dyspnea (0.638) symptom scores.
Conclusion: The EQ-5D is responsive to the recovery from a moderate COPD exacerbation.
ª 2011 Elsevier Ltd. Open access under the Elsevier OA license.Introduction
Many patients with chronic obstructive pulmonary disease
(COPD) experience recurrent exacerbations with increased
breathlessness and/or wheeze, often accompanied by
greater volume of sputum and increased cough. Exacerba-
tions greatly contribute to a decline in health-related
quality of life.1e4 A main objective of treatment is to
reduce the frequency and severity of exacerbations. To
fully appreciate the effectiveness of treatments, the full
health-related quality of life gains that result from this
reduction should be included. In clinical studies this is often
not done, because health-related quality of life is
measured only at regularly scheduled intervals, but not
during exacerbations. Specific studies that measure quality
of life during an exacerbation are necessary.
Health-related quality of life can be estimated with
disease-specific or generic instruments. Disease-specific
instruments were designed to detect even small changes in
the patient’s health-related quality of life. However, health
economists prefer the use of generic instruments, because
they enable the comparison of health states as well as the
benefits of medical interventions across diseases. To express
these benefits in terms of quality-adjusted life years (QALYs),
utility weights are assigned to health states.5 Perfect health,
by definition, has a utility of 1, while death has a utility of 0.
Health states may also be considered worse than death and
have negative utility. A year spent in perfect health equals
one QALY.
Among the most widely used instruments to measure
utilities is the European quality of life scale (EQ-5D).6
The EQ-5D has been validated and applied in the stable
phase of COPD.7e11 In addition, O’Reilly et al. andMenn et al.
applied the instrument in patients with severe exacerba-
tions, requiring hospital admission.12,13 A paper by Paterson
et al. contains limited information on the use of the EQ-5D at
the onset and after treatment of type-1-exacerbations
(Anthonisen classification) of chronic bronchitis.14
However, in order to capture the full health-related
quality of life loss during an exacerbation, the entire course
of recovery must be described. In the current paper, we
evaluated the ability of the EQ-5D to detect the recovery
from a moderate COPD exacerbation, requiring antibiotic or
systemic steroid therapy but no hospital admission15 over
six weeks: at the onset of the exacerbation, during treat-
ment, and after recovery.
We tested the changes in the EQ-5D utility index scores
over time and compared the effect sizes to those of several
symptom scores, peak flow and the use of rescue medica-
tion. The change in shortness of breath symptom score aswell as medication use were expected to be most closely
related to the EQ-5D score, since they have the strongest
effect on quality of life. We also, tentatively, estimated the
health loss due to a moderate exacerbation.
Methods
The EQ-5D data were collected alongside an exacerbation
study that was primarily conducted to assess the respon-
siveness of a previously developed cough and sputum
assessment questionnaire, the CASA-Q.16
Patients and setting
After institutional reviewboardapproval andwritten informed
consent, 65 male and female COPD and/or chronic bronchitis
patients were enrolled at 7 study sites in the United States.
They had to be 40 years or older and had to be current or
former smokers with a history of at least 10 pack-years.
Patients were enrolled when they visited the outpatient clinic
within 48 h of symptom onset. An exacerbationwas defined as
the increase or new onset of at least two lower respiratory
symptoms related to COPD, with at least one symptom lasting
three or more days and requiring a change in treatment. An
exacerbation was defined as moderate if the change in treat-
ment included the prescription of antibiotics and/or systemic
steroids. Exacerbations that required hospital admission were
considered severe and were excluded from this study.
Also excluded were patients with significant other
diseases which could influence the results of the study or
the subject’s ability to participate in the study. Other
exclusion criteria were a history of asthma, cystic fibrosis,
bronchiectasis, active pneumonia or tuberculosis.
Design
The study was designed as a prospective cohort study. The
change in EQ-5D scores over a period of 6 weeks was
observed. In addition to the visit at enrollment (visit 1),
patients were evaluated at day 7 (visit 2), day 14 (visit 3)
and day 42 (visit 4). The interval between visits was allowed
to vary by up to 3 days. The patients were treated for their
exacerbation at the discretion of the investigator according
to the standards of care.
Measurements
At each visit participants completed the EQ-5D, in which
health status is described by ticking off one of three levels
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“extreme problems”) on five dimensions: mobility, self-
care, usual activities, pain/discomfort and anxiety/
depression. Using a set of weights (value set) for each level
of functioning in each dimension, the descriptive informa-
tion can be converted into a single utility index.
Since this study was conducted in the United States, the
US value set was used to calculate utilities.17 Patients were
also asked to rate their health on the EQ-5D Visual Analog
Scale (VAS), which ranges from 0 (worst imaginable health
state) to 100 (best imaginable health state).
In the daily diary, patients recorded how short of breath
they were, how often they coughed and how often they
brought up sputum using a 5-point response scale ranging
from “not at all” to “a lot”, or “never” to “always”. The diary
also contained measurements of morning peak flow (before
taking medication) and use of rescue medication. Pre- and
post-bronchodilator spirometry was performed at visit 4.
Patient’s and Clinician’s Global Impression of Change (PGI-C,
CGI-C) were measured at visit 4: they rated the change in
cough and sputum symptoms on a seven-point scale ranging
from “very much worse” to “very much better”.Table 1 Baseline characteristics.
N 59
Age: mean (SD) 61.1 (10.4)
Female: n (%) 40 (67.8)
Current smoker: n (%) 32 (54.2)
Pack-years: mean (SD) 60.14 (30.12)
Number of co-morbidities: mean (SD) 6.69 (3.34)
Charlson co-morbidity index score: mean
(SD)
0.66 (0.921)
Diagnosis COPD: n (%) 54 (91.5)
Diagnosis chronic bronchitis only: n (%) 5 (8.5)
GOLD classification at visit 4a
Not obstructed: n (%) 19 (33.3)
Stage 1 (Mild): n (%) 2 (3.5)
Stage 2 (Moderate): n (%) 14 (24.6)
Stage 3 (Severe): n (%) 13 (22.8)
Stage 4 (Very severe): n (%) 9 (15.8)
SD: standard deviation.
a Two patients with missing lung function measurements.Statistical analysis
Changes in the proportions of patients that report either
“no problems” or “some problems”/“extreme problems” on
the EQ-5D between baseline and visit 4 were analyzed using
McNemar’s test. Baseline EQ-5D VAS and utility index was
defined as the score at either visit 1 or 2, whichever was
lower. This baseline value captured the point in time when
the impact of the exacerbation was most severe.
Mean (standard deviation, SD) scores for EQ-5D VAS and
utility index scores were calculated at all visits and dis-
played graphically.
Responsiveness was expressed as the Standardized
Response Mean (SRM) - defined as the average change
between EQ-5D index scores at baseline and visit 4 divided
by the standard deviation of that change. SRM of the EQ-5D
was compared to the corresponding SRM of the various
symptom scores derived from the diary items. We used the
interpretation of Cohen, where 0.2 is indicative of a small
effect, 0.5 of a medium and 0.8 of a large effect.18
Using a change in morning peak expiratory flow (between
the first week and the last week) above the median as an
external criterion to define a greater improvement, we
assessed whether EQ-5D scores improved more in those with
a greater improvement in peak flow than in those with
a smaller improvement in peak flow, i.e. whether the SRM of
the EQ-5D index score was greater in those with a greater
improvement in peak flow. Similarly, SRM for EQ-5D index
scores were calculated for the cohort divided into two groups
by 1) patient global impression of change ((very) much better
versus the remaining response options), 2) clinician global
impression of change ((very) much better versus the remain-
ing responseoptions), 3) symptomscore (change inmeandaily
symptom score between the first week and the last week
below and above the median), and 4) rescue medication use
(change inmean daily number of puffs between the firstweek
and the lastweekbelowandabovemedian).The standardized
difference between the above mentioned pairs wascalculated as the difference between the mean change from
baseline at visit 4 divided by the pooled standard deviation of
these change scores. Differences in change from baseline in
EQ-5D index score between the pairs were tested by t-tests.
Repeated measures analysis was performed to analyze
the change from baseline to visit 3 and 4 in EQ-5D index
scores using the SAS procedure PROC MIXED with covariance
modeled as “unstructured”. The model included time
(visits), EQ-5D score at baseline, age, gender, smoking
status, lung function at visit 4 (as an approximation of lung
function without exacerbation), diagnosis (chronic bron-
chitis/COPD) and co-morbidity (either the Charlson Co-
morbidity Index score19 or the number of co-morbidities),
as well as the interaction of baseline EQ-5D score and time.
For each patient, the QALY loss due to the exacerbation
was calculated by subtracting the QALYs during the exac-
erbation from the QALYs the patient would have had if the
COPD had remained stable during the same period. The
latter was approximated by taking the highest score at any
of the visits. The number of QALYs was calculated by
summing the days under observation weighted by their
utilities (using linear interpolation).
Results
Patients
In total 59 of the 65 subjects completed the study and were
included in the analysis (Table 1). Three patients (hospital
admissions (n Z 2) and concomitant lung cancer (n Z 1))
proved to be ineligible after being included in the study.
Three others discontinued their cooperation after the first
visit. One patient had one missing value, but his other three
values were included in the analysis.
EQ-5D dimensions
The proportion of patients with “no problems” significantly
increased over time on all dimensions (Fig. 1). P-values for
Fig. 1 Proportion of patients reporting no problems (1), some
problems (2) or extreme problems (3) on each EQ-5D dimension,
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extremeproblems betweenbaseline and visit 4were 0.008 for
the mobility dimension, 0.007 for self-care, 0.021 for usual
activities, 0.012 for pain and0.006 for anxietyanddepression.
At any visit the majority of patients had problems
performing their usual activities and felt pain and anxiety.
A minority experienced problems when performing self-
care. No problems on any dimension were reported by 4
respondents (6.8%) at baseline, by 9 respondents (15.3%) at
visit 3 and by 10 respondents (16.9%) at visit 4.
EQ-5D VAS scores
For 17% of patients, VAS scores decreased from visit 1 to visit 2.
However, most of the mean improvement in VAS scores
occurredbetweenthesemeasurements.Table2showsthat the
highest VAS scores were reported for visit 4. The differences
between baseline and visits 3 and 4 were highly significant.
EQ-5D index scores
There was a highly significant improvement in mean utility
index scores (Table 2). Patients improvedmost between visits
2 and 3. The utility index of 76% of patients improvedbetween
baseline and visit 3, while it deteriorated in 8.5%. Table 2
shows that the mean of each patient’s lowest index score
was lower than the mean at visit 1, following the fact that
quality of life deteriorated in 25% of patients after treatment
had started. Overall, VAS scores showed improvement before
the utility index scores started to do so. Fig. 2 presents the
course of moderate exacerbations over time.
The repeated measures analysis showed that the
improvement of the EQ-5D utility index score at visits 3 and
4 since baseline was predicted by its baseline value, the
patient’s gender and smoking status (goodness of fit of the
model: 2 res log likelihood Z 135.9). Patients with
a higher baseline utility index score showed less improve-
ment. Women did not recover as well as men (difference:
0.07242, p Z 0.0121). Current smokers covered a larger
distance between baseline and recovery than former non-
smokers (difference 0.05170 p Z 0.0602). As before, no
significant difference was found between visit 3 and 4. Age
(p Z 0.9694), post-bronchodilator FEV1 (in % predicted) at
visit 4 (pZ 0.268) and co-morbidity (0.6229) were dropped
from the final model because they were not significantly
associated with recovery of utility values.
Health loss
Participants lost on average 0.00896 QALY (SD 0.0086) or 3.27
(SD 3.13) quality-adjusted life days during the exacerbation.
The largest individual loss was 0.0364 QALY or 13.29 quality-
adjusted life days. Two patients incurred no loss of QALYs
compared to the situation with stable COPD, because they
had the same score throughout the study.
Responsiveness
A medium to large SRM for the change from baseline in
utilities was observed (Table 3). The SRM was comparable
for the symptom scores on cough and shortness of breathby visit.
Table 2 EQ-5D VAS and utility index scores per visit.
EQ-5D VAS scores
Visit Mean SD Range
Lowesta 34.75 25.244 1e85
1 36.68 25.244 1e85
2 48.03 32.787 3e100
3 48.19 32.336 5e100
4 50.25 31.840 3e100
Highestb 55.81 34.190 5e100
EQ-5D VAS, differences in scores between visits
VAS Difference (SD) P-value
Visit 2 e Visit 1 11.356 (20.678) <0.0005
Visit 3 e Visit 2 0.153 (14.539) 0.936
Visit 4 e Visit 3 2.068 (14.027) 0.262
Visit 3 e Lowesta 13.441 (21.477) <0.00002
Visit 4 e Lowestb 15.508 (19.754) <0.000001
EQ-5D utility index score (US tariff)
Visit Mean SD Range
Lowesta 0.651 0.213 0.165e1.00
1 0.683 0.209 0.165e1.00
2 0.726 0.216 0.165e1.00
3 0.768 0.169 0.202e1.00
4 0.760 0.181 0.202e1.00
Highestb 0.828 0.148 0.202e1.00
EQ-5D utility index score, differences in scores between visits
Difference (SD) P-value
Visit 2 e Visit 1 0.0381 (0.1560) 0.068
Visit 3 e Visit 2 0.0413 (0.1523) 0.044
Visit 4 e Visit 3 0.0073(0.1574) 0.722
Visit 3 e Lowesta 0.1167 (0.1527) <0.0000002
Visit 4 e Lowesta 0.1094 (0.1676) <0.000001
a Lowest Z value at visit 1 or 2, whichever is lower.
b Highest Z highest value at any visit.
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Fig. 2 EQ-5D utility index scores over the course of
a moderate exacerbation: mean over all patients, patient with
the best improvement and patient with the worst deteriora-
tion, the most volatile patient.
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ratory peak flow.
The largest standardized difference in EQ-5D utility
change was found in the patients stratified by their rescue
medication use (Fig. 3). The improvement in EQ-5D utility
was significantly greater in patients who had a greater
reduction in rescue medication use than in those who had
a smaller reduction in rescue medication use (p Z 0.018).
Significance was almost reached for the improvement in
EQ-5D utility stratified by improvement of shortness of
breath (p Z 0.051) and peak flow (p Z 0.058).
The standardized differences were negative for
participants with a good or very favorable patient’s or
clinician’s impression of change compared to the rest of
the sample. However, the differences in change in EQ-5D
index scores between these groups were not significant
(p Z 0.128 and p Z 0.657 respectively). Neither were
those between groups with improvements in cough and
sputum scores above and below the median (p Z 0.144
and p Z 0.594).
Table 3 Standardized response mean: comparison
between the EQ-5D, symptoms scores, rescue medication
use and morning peak expiratory flow.
Mean change SD of change SRM
Utility index score
EQ-5Da 0.109 0.168 0.653
Symptom scores
Sputumb 0.196 0.609 0.322
Coughb 0.395 0.673 0.587
Shortness of breathb 0.588 0.207 0.638
Rescue medicationb 0.708 2.068 0.343
Expiratory Peak flowb 14.144 52.673 0.269
SRM Z standardized response mean.
a Change between lowest score at visit 1 or 2 and score at
visit 4.
b Change between first and last week of study.
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This study has shown that the EQ-5D index score is
responsive to recovery from a moderate COPD exacerba-
tion. When the exacerbation was at its worst, the average
utility score was 0.651. It increased to 0.768 on day 14,
after which it remained largely stable until the final visit at
6 weeks. Three-quarters of patients experienced an
improvement in health-related quality of life after the
worst day of the exacerbation. The mean total improve-
ment was statistically significant and can be considered
medium-sized to large according to Cohen’s classification.
As the EQ-5D improved, so did the VAS and symptom
scores, peak flow and rescue medication use. However, the
SRM for the change in EQ-5D index score was generally
larger than for peak flow, rescue medication and phlegm
symptom scores. This was probably caused by the index
covering more aspects of health-related quality of life.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
PGI-C (-0.413)
CGI-C (-0.170)
Sputum (0.140)
Cough (-0.395)
Shortness of breath (0.518)
Expiratory peak flow (0.505)
Rescue medication use (0.645*)
Standardized response mean
Patients with more improvement Patients with less improvement
Fig. 3 Standardized Response Means of EQ-5D utility index
scores, by subgroups of patients. Black bar: subgroup of
patients with more improvement, where more improvement is
defined as patients whose global impression of change is
“(very) much better” or who have a change in mean daily
symptom score, mean daily number of puffs of rescue medi-
cation, or mean daily morning peak flow above the median.
Gray bar: subgroup of patients with less improvement (i.e. the
remaining patients). The standardized difference between
subgroups is given between brackets. *Difference is statisti-
cally significant, t-test p < 0.05.The responsiveness of the EQ-5D was also demonstrated
by greater improvements in EQ-5D scores among the
patients with a greater reduction in the use of rescue
medication, a greater improvement in morning peak expi-
ratory flow and a greater improvement in shortness of
breath symptoms. In contrast, change in EQ-5D scores was
not better for patients with better scores on the patient’s
global impression of change or the clinician’s global imp-
ression of change.
All five dimensions of the EQ-5D contributed significantly
to the mean improvement in the EQ-5D index score. The
mobility dimension showed the largest improvement. Most
participants had problems with usual activities and expe-
rienced pain and anxiety even at the last visit. This may
reflect their underlying impairment due to their chronic
respiratory disease.
The EQ-5D showed a disutility at baseline in almost all
patients.
COPD exacerbations are not necessarily at their most
severe at the moment when patients first consult a physi-
cian. Indeed, our results showed a considerable proportion
of patients whose EQ-5D scores worsened during the first
week. When studying an instruments ability to respond to
the recovery from an exacerbation, the most informative is
the path from the lowest point of the exacerbation,
whenever this occurs, to its resolution weeks later. This is
what we did in our repeated measures analysis and SRM
calculations, where baseline was defined as the score at
either visit 1 or 2, whichever was lower. However, differ-
ences between visit 1 and visits 3 and 4 were highly
significant as well.
In a tentative calculation, it was derived that the
average QALY loss during the exacerbation was 0.00896, or
3.27 quality-adjusted life days. This calculation is sensitive
to the estimate of the utility value during the stable phase
of the disease. Since we did not have actual data on quality
of life during the stable phase, we chose to compare the
health-related quality of life that each patient actually
experienced, with the highest individual score during the
study e as an approximation of the quality of life during
stable disease. The results of the calculation must be
considered a preliminary estimate.
It is possible that patients had not completely recovered
at the end of the study to their stable health-related quality
of life levels, although improvement appeared to reach
a plateau after two weeks. Furthermore, an exacerbation
may cause permanent damage to the patient’s health. This
would mean that our estimate of quality of life loss would
have been too low. To capture the entire loss, patientswould
have to fill out the EQ-5D questionnaire during the stable
phase, at times when no exacerbation is expected. Another
approach would be to collect values for COPD health profiles
that contain a description of the severity of the COPD during
the stable phase and a description of the exacerbation
profile, as was recently reported by Rutten-van Mo¨lken
et al.20 The deduction in utility value due to a non-severe
exacerbation in this study was 0.010 (Dutch value set);
compared to 0.009 (US value set) in the current study.
As expected, the utility scores in our study were much
higher than those reported by O’Reilly et al. for patients
experiencing a severe exacerbation in Britain. At the onset,
the mean EQ-5D utility value for their group was negative
Is the EQ-5D responsive to recovery from a moderate COPD exacerbation? 1201(0.077, according to the UK tariff) and nearly two-thirds
of respondents indicated that they felt “worse than
death”.12 At discharge the mean utility had improved to
0.576 with only 5% of patients indicating a health-related
quality of life “worse than death”. However, within the
three months after discharge quality of life deteriorated
markedly again. We did not find indications of a deterio-
rating health after an initial improvement in our study, but
our observation period was limited to six weeks. Another
study in patients with a severe exacerbation was performed
in Germany by Menn et al., who also concluded that the
EQ-5D is suitable for measuring health-related quality in
this patient group.13 However, they found much higher
utility scores than O’Reilly. The authors suggested that
patients in Germany might be admitted to the hospital
relatively early, which would make average inpatient
exacerbations milder than in the UK. Paterson et al.
assessed the difference between utility scores in chronic
bronchitis patients before and shortly after treatment for
a type-1-exacerbation,14 which could in this case appar-
ently be classified as “moderate”. Unfortunately, they did
not present utility scores during the exacerbation. They
did, however, report the change between the start and the
end of treatment e as 0.17 according to the UK value
set e which is comparable to our estimate if it had been
based on the same value set.
Respondents completed the CASA-Q instrument16 before
the EQ-5D. Concentrating on respiratory symptoms in the
CASA-Q might have made respondents more sensitive to
possible changes on the EQ-5D dimensions, which would
increase the responsiveness of the latter questionnaire.21,22
On the other hand, examples have been shown of an effect
in the opposite direction, by inducing respondents to
exclude considerations about respiratory problems from
their answers to the EQ-5D because the impact of symptoms
had already been covered by the other questionnaire.22,23
However, studies on ordering effects in generic and
specific quality of life questionnaires did not find any
significant or relevant effects in a number of diseases.24e28
We did not investigate the presence and magnitude of the
question order effect.
We had two reasons for not assembling a control group of
patients without exacerbations to compare to the patients
with exacerbations. Randomization into groups with and
without exacerbation was impossible and we could not
ensure that the control group would be sufficiently
comparable. It would have been possible to enroll patients
and wait until an exacerbation developed. However, this
lengthy and costly procedure was not considered worth-
while since utility index score values in patients outside of
exacerbations are known to be stable.8 Therefore, any
significant change in mean utility during the exacerbation
can be interpreted as a consequence of (the recovery from)
the exacerbation.
As a generic instrument for health-related quality of life
measurement, the EQ-5D was developed for the comparison
of quality of life and of the effects of healthcare inter-
ventions across diseases. We do not recommend its use in
routine clinical practice. The EQ-5D was not designed for
tracking an individual patient’s response to treatment or as
a measure on which treatment adjustments could be based.
Our study does, however, have implications for conductingfuture cost-effectiveness studies. In contrast to current
practice these studies can and should include the utility
gains resulting from a reduction in exacerbations. It has
been argued that the EQ-5D is not responsive to small
changes in health of COPD patients,8,9 but our study has
shown that it was responsive over a moderate
exacerbation.
In conclusion, the EQ-5D was found to be responsive to
the recovery from a moderate COPD exacerbation. The
greatest improvement in utility scores was reached within
two weeks after the onset of the exacerbation. The EQ-5D
was more responsive than expiratory peak flow, rescue
medication and sputum symptom scores and equally
responsive as cough and dyspnea symptoms scores.Conflicts of interest
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